IPATF - ImmunoPrecise Antibodies Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4109
-0.0361 (-8.08%)
At close: 3:06PM EDT
Stock chart is not supported by your current browser
Previous Close0.4470
Open0.4432
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4109 - 0.4432
52 Week Range0.3821 - 0.7573
Volume1,850
Avg. Volume10,392
Market Cap26.995M
Beta (3Y Monthly)-1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.0840
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group

    ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million

    VICTORIA , Aug. 28, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for the year ended April 30, 2019.  The financial statements and related Management's Discussion and Analysis ("MD&A") can be viewed on SEDAR at www.sedar.com. This represents a 100% increase in revenue as a result of its completed acquisitions of IPA Europe (formerly ModiQuest Research), and IPA's ability to grow its core business and expand into higher revenue service offerings in therapeutic discovery. Gross Margin ImmunoPrecise increased its gross margin to $5,294,634 from $2,451,026 in 2019.

  • CNW Group

    ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

    VICTORIA , Aug. 1, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces the launch of its High Value Target Scientific Committee which will strengthen the scientific oversight and methodological practice within Talem. Initial electees to the committee include Dr. Ilse Roodink (IPA Europe), Dr. Zalan Szabo (U-Protein Express, an IPA Company), Dr. Andra Li (IPA Canada), and Dr. Jennifer Bath (Talem, IPA Ltd).

  • CNW Group

    ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

    VICTORIA , July 15, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that it has entered into a new antibody discovery collaboration with Entos Pharmaceuticals Inc., to develop a therapeutic candidate against an undisclosed, immuno-oncology target, by leveraging ImmunoPrecise's proprietary B cell Select™ platform.

  • CNW Group

    ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

    ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

  • CNW Group

    ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's Proprietary High-Throughput B-Cell Select™ and DeepDisplay™

    VICTORIA , May 30, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that its proprietary, high-throughput B-cell and phage display platforms have garnered a lot of attention as of late, and for a good reason. In recent weeks and months, IPA has been engaged by several large pharmaceutical companies to conduct work using transgenic animals from Ligand Pharmaceutics (distributors of OmniRat™, OmniMouse™, OmniFlic™, and OmniChicken™), Ablexis (distributors of AlivaMab®), Harbour BioMed (distributors of Harbour Mice®, an undisclosed transgenic knock-out animal, Alloy Therapeutics (Distributors of Alloy Mice®) and Trianni (distributors of Trianni Mice®).

  • CNW Group

    ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor

    U-Protein Express, a wholly-owned ImmunoPrecise Antibodies subsidiary, in Utrech, Netherlands , announced that it has obtained an exclusive license from Stanford University to manufacture and sell a novel protein, Wnt surrogate Fc, a substitute for a protein known as Wnt. Wnt proteins are involved in signalling cells to divide and develop, and the Wnt surrogate can be used as a growth factor in cell culture media for, among other purposes, the growing of organoids.

  • GlobeNewswire

    Uptick Newswire Hosts ImmunoPrecise Antibodies Ltd. on the Stock Day Podcast to Discuss Their Rapid Growth in the Antibody Discovery Space

    Uptick Newswire Stock Day Podcast welcomed ImmunoPrecise Antibodies Ltd. (IPATF) (“the Company”), a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. President and CEO, Dr. Jennifer Bath, joined Stock Day host Everett Jolly. Jolly began the interview by asking Dr. Bath to provide some background information on herself and the Company.

  • CNW Group

    ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

  • CNW Group

    ImmunoPrecise Appoints Andy Nixon to Board of Directors

    VICTORIA , April 11, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has appointed Andy Nixon , Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, as a member of its board of directors. Dr. Nixon is a pharma executive with 20 years of industry experience and a proven track record of leading cross-functional teams to solve complex problems.

  • CNW Group

    TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies

    VICTORIA , April 9, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases. The alliance is focused on the discovery of novel human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels. "We are pleased to work with ImmunoPrecise, utilizing their customized phage library technology," said Douglas Kahn , TetraGenetics Chairman and CEO.

  • CNW Group

    ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

    VICTORIA , April 4, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts -based subsidiary, Talem Therapeutics (Talem). Talem is focused on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies targeting neurology, immuno-oncology, gastroenterology, inflammation, and rare/specialty diseases.

  • CNW Group

    ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

    ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

  • CNW Group

    ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform

    ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform

  • CNW Group

    ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results

    VICTORIA , March 27, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "ImmunoPrecise") (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q3 ended January 31, 2019 . During the three months ended January 31, 2019 , the Company increased revenues to $2,695,583 from $1,723,308 in 2018. This represents a 56% increase in revenue and stems from the acquisitions of U-Protein and ModiQuest, the Company's ability to grow its core business and expand its market share in Europe , and an increase in projects for the B-cell lab.

  • GlobeNewswire

    Positive Results and New Technology Give Rise to Antibody Dominance

    POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 -- Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot.

  • CNW Group

    ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV

    ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV

  • CNW Group

    ImmunoPrecise Antibodies Announces DTC Eligibility

    VICTORIA, BC , Feb. 28, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States . DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies.

  • CNW Group

    ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies

    ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies

  • CNW Group

    ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test

    VICTORIA , Feb. 19, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New Diagnostics (FIND) where IPA developed rabbit monoclonal antibodies (mAbs) for assessment in FIND's sensitive new immunoassay diagnostic test for tuberculosis (TB). IPA developed rabbit monoclonal antibodies, using its B cell Select platform, that recognize lipoarabinomannan (LAM), a lipopolysaccharide target and biomarker for TB that can be excreted in the urine of individuals with the disease.

  • CNW Group

    Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts

    VICTORIA , Feb. 14, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office in Cambridge, Massachusetts . ImmunoPrecise Antibodies Ltd is a Canadian contract research organization providing a range of services, including antibody discovery, manufacturing, optimization, engineering and pre-clinical studies. "With production sites in Canada and the Netherlands , and the executive headquarters in the North Dakota , establishing a base in the Boston / Cambridge area, a powerhouse for biotech and pharma, is a strategic next step for IPA.

  • CNW Group

    ImmunoPrecise Antibodies Ltd. Increases Antibody Discovery Capabilities with Addition of Integrated Laboratory Equipment for High-throughput Antibody Screening

    VICTORIA , Feb. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based screening. The demand for accelerated development of next-generation antibodies that recognize evermore challenging targets and have improved activities has prompted IPA to purchase further instrumentation to evaluate more antibody characteristics in a multiplexed, high-throughput way.  Traditional antibody screening tools report on binding one target at a time, which makes the discovery process time consuming and can require large amounts of target protein. The Intellicyt iQue allows IPA scientists to significantly reduce lead discovery time while conserving valuable samples and reducing reagent cost.

  • CNW Group

    ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer

    VICTORIA , Jan. 14, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as Chief Financial Officer. Lisa Helbling brings over 30 years of experience in accounting, financing, and business development within the public markets and has a demonstrated ability to manage financial and operational challenges while governing a dynamic and growing business. Helbling previously served as the CFO at Anchor Ingredients, a specialty commodity company that provides end-to-end ingredient supply from farm origination, value added processing and distribution to human and pet food markets.

  • CNW Group

    ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019

    ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019

  • CNW Group

    Immunoprecise Doubles Q2 Revenue From Q2 2017

    VICTORIA , Dec. 31, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "ImmunoPrecise") (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q2 ended October 31, 2018 . During the three months ended October 31, 2018 , the Company increased revenues to $2,716,791 (YTD: $5,589,576 ) from $1,316,261 (YTD: $1,907,319 ) in 2017. This represents a 106% (YTD: 193%) increase in revenue from the Company's increased capacity, expanded market share in Europe , increased high margin projects at its B-cell lab and the acquisitions of U-Protein Express and ModiQuest Research.

  • CNW Group

    ImmunoPrecise Hires Jason Orloske as Vice President Operations

    VICTORIA , Dec. 26, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies Global Division reporting directly to Dr. Jennifer Bath , CEO and President. As Vice President of Operations, Jason Orloske , PMP, CSP, is responsible for operationalizing strategic initiatives and continuing to drive growth. Jason is a transformational business leader with almost 20 years' experience in project portfolio management and strategic delivery.